BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:[ U.S. CDMRP – Clinical Trial Award for Emerging Viral Diseases 
 and Respiratory Health | Research Funding ]
DTSTART;VALUE=DATE:20200608
DTSTAMP:20260506T080510Z
UID:29f260856889245abbcfb4aa7a1483fee0b1af47c988d063986ae14c
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the Peer-Reviewed M
 edical Research Program (PRMRP) Awards. The PRMRP Clinical Trial Award for
  Emerging Viral Diseases and Respiratory Health supports the rapid impleme
 ntation of clinical trials with the potential to have a significant impact
  in one or more of the Topic Areas related to Emerging Viral Diseases and 
 Respiratory Health\, particularly as they relate to COVID-19. These topic 
 areas are listed at the end of this announcement.\n\nClinical trials may b
 e designed to evaluate promising new products\, pharmacologic agents (drug
 s or biologics)\, devices\, clinical guidance\, and/or emerging approaches
  and technologies. Proposed projects may range from small proof-of-concept
  trials (e.g.\, pilot\, first in human\, Phase 0)\, to demonstrate feasibi
 lity or inform the design of more advanced trials\, through large-scale tr
 ials to determine efficacy in relevant patient populations.\n\nRelevance t
 o the healthcare needs of military Service members\, Veterans\, military b
 eneficiaries\, and/or the American public is a key feature of this award. 
 Applications are required to include an explanation of how the proposed pr
 oject has relevance to military health.\n\nFunding:        No fundin
 g ceiling is set.\n\nDuration:      4 years\n\nEligibility: Applicants
  from international organizations or institutions are eligible to apply\, 
 and there are no citizenship restrictions. PI applicants must be independe
 nt investigators at or above the level of Assistant Professor (or equivale
 nt).\n\nHow to Apply: Pre-applications are submitted through the eBRAP pla
 tform. They should contain contact information\, a letter of intent\, and 
 a list of collaborators and key personnel as suggested on the platform. Fu
 ll applications (by invitation) will be made via a Grants.gov workspace. F
 ull application packages can be downloaded from Grants.gov at any time.\n\
 nPre-Application Deadline: 08-Jun-2020\, 5:00 p.m. EST\nFull Application D
 eadline: 22-Jun-2020\, 11:59 p.m. EST\n\nGrants.gov Funding Opportunity Nu
 mber: W81XWH-20-PRMRP-CTA-COV\n\nFurther information\n\n	To see the progra
 m announcement\, navigate to the search page on Grants.gov and search for 
 the Opportunity Number W81XWH-20-PRMRP-CTA-COV\n	For questions about the e
 BRAP or Grants.gov platforms\, contact the Research Office.\n\n\nFY20 Topi
 c Areas: Emerging Viral Diseases and Respiratory Health\n\n\n	On demand id
 entification\, isolation\, characterization and manufacturing of antibodie
 s (monoclonal or polyclonal) from peripheral blood mononuclear cells (PBMC
 s) collected from patients with coronavirus disease 2019 (COVID-19).\n	Dev
 elopment of a wearable sensor that provides real-time diagnostics that can
  be used as a point of care for emerging viral diseases to predict illness
  before onset of symptoms.\n	Surveillance and predictive modeling tools th
 at leverage artificial intelligence approaches to predict outbreaks and ep
 idemics and support strategies for mitigating the threat of COVID-19.\n	Tr
 iage of care for COVID-19 patients requiring access to resource-intensive 
 interventions.\n	Research to understand novel molecular and biological mec
 hanisms of COVID-19 health impacts (e.g.\, microbiome) and identification/
 validation of biochemical\, physiological\, or combined biomarkers for eva
 luating short- and long-term health impacts from COVID-19.\n	Research to d
 etermine direct and indirect impacts of COVID-19 on military readiness and
  unit climate\; interpersonal/family dynamics\; behavioral and mental heal
 th issues such as depression\, suicide\, anxiety\, and loneliness and othe
 r key risk factors such as substance abuse and risky health-related behavi
 ors.\n	Research on the etiology and prevention of acute respiratory distre
 ss syndrome (ARDS) caused by host responses to coronaviruses\, particularl
 y COVID-19.\n	Development of improved methods for assessing and treating l
 ung injury due to coronaviruses\, particularly COVID-19.\n	Novel and/or in
 novative detection technologies or therapeutics to reduce the incidence an
 d/or severity of ARDS and/or other lung injury secondary to coronaviruses\
 , particularly COVID-19.\n	Development of biomarker metrics to associate t
 he long-term health outcomes of virus-induced ARDS with degradation of phy
 siological and physical performance.\n	Ventilation and Extracorporeal Life
  Support approaches and technologies to support lung function or airway ma
 nagement in response to COVID-19 that increase survivability and/or minimi
 ze care provider burden or exposure.\n	Pharmacological and biologic interv
 entions for COVID-19 induced complications\, including ARDS and related se
 quelae.\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR